Literature DB >> 25047535

Physicians' attitude toward recurrent hypercalcemia in terminally ill cancer patients.

Akira Shimada1, Ichiro Mori, Isseki Maeda, Hidekazu Watanabe, Nobutaka Kikuchi, Hansheng Ding, Tatsuya Morita.   

Abstract

BACKGROUND: There is no consensus regarding whether cancer-induced hypercalcemia should be treated up until the patient's death. The primary aim of this study was to clarify physicians' attitude toward treating recurrent hypercalcemia in terminally ill cancer patients and associated factors.
METHODS: A nationwide, cross-sectional survey was performed involving 757 physicians of the Japanese Society for Palliative Medicine. Physicians' attitude toward treating hypercalcemia in terminally ill patients was assessed based on the response to the question: do you agree that you provide medical treatment for recurrent hypercalcemia up until a patient's death? As the potential determinants of physicians' attitudes, we examined their characteristics, beliefs about hypercalcemia, and beliefs about a good death.
RESULTS: We obtained a total of 380 (50.2%) analyzable responses. A total of 163 physicians (43%) agreed that hypercalcemia should be treated up until the patient's death, while the remaining 217 physicians (57%) disagreed. The independent determinants of the attitude included the following: physicians' specialty, belief that hypercalcemia treatment improves pain, belief that hypercalcemia treatment improves nausea, belief that hypercalcemia treatment improves quality of life, belief that hypercalcemia treatment prolongs life, belief that the effect of hypercalcemia treatment reduces gradually, belief that death with hypercalcemia is less distressing, and the perception that being mentally clear is important for a good death.
CONCLUSION: Japanese physicians had different attitudes toward treating hypercalcemia in terminally ill patients. Physicians' beliefs about the efficacy of medical treatment for hypercalcemia markedly influenced their attitudes. Clarifying evidence on the effect of hypercalcemia treatment on patients' symptoms and prognoses is strongly encouraged.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25047535     DOI: 10.1007/s00520-014-2355-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  18 in total

Review 1.  Modern management of malignant hypercalcemia.

Authors:  Susan B Legrand
Journal:  Am J Hosp Palliat Care       Date:  2011-07-01       Impact factor: 2.500

2.  Practices and attitudes of Japanese oncologists and palliative care physicians concerning terminal sedation: a nationwide survey.

Authors:  Tatsuya Morita; Tatsuo Akechi; Yuriko Sugawara; Satoshi Chihara; Yosuke Uchitomi
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial.

Authors:  Eduardo Bruera; David Hui; Shalini Dalal; Isabel Torres-Vigil; Joseph Trumble; Joseph Roosth; Susan Krauter; Carol Strickland; Kenneth Unger; J Lynn Palmer; Julio Allo; Susan Frisbee-Hume; Kenneth Tarleton
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

4.  Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.

Authors:  J J Body; I Louviaux; J C Dumon
Journal:  Support Care Cancer       Date:  2000-09       Impact factor: 3.603

5.  Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies.

Authors:  T Morita; I Hyodo; T Yoshimi; M Ikenaga; Y Tamura; A Yoshizawa; A Shimada; T Akechi; M Miyashita; I Adachi
Journal:  Ann Oncol       Date:  2005-01-31       Impact factor: 32.976

6.  Feasibility of administering zoledronic acid in palliative patients being cared for in the community: results of a pilot study.

Authors:  H K Marr; C R Stiles; M A Boyar; T C Braun; N A Hagen; C Janzen; L M Whitten; J L Pereira
Journal:  Curr Oncol       Date:  2010-04       Impact factor: 3.677

7.  Effect of parenteral hydration therapy based on the Japanese national clinical guideline on quality of life, discomfort, and symptom intensity in patients with advanced cancer.

Authors:  Takashi Yamaguchi; Tatsuya Morita; Takuya Shinjo; Satoshi Inoue; Chizuko Takigawa; Etsuko Aruga; Kazuhiko Tani; Takashi Hara; Yoichiro Tamura; Akihiko Suga; Seiji Adachi; Hideki Katayama; Iwao Osaka; Yoshiyuki Saito; Nobuhisa Nakajima; Takashi Higashiguchi; Tatsuhiko Hayashi; Takeshi Okabe; Hiroyuki Kohara; Tomohiro Tamaki; Yoshikazu Chinone; Hideki Aragane; Yoshiaki Kanai; Natsuki Tokura; Takuhiro Yamaguchi; Takashi Asada; Yosuke Uchitomi
Journal:  J Pain Symptom Manage       Date:  2012-06       Impact factor: 3.612

Review 8.  Systematic review of bisphosphonates for hypercalcaemia of malignancy.

Authors:  Y Saunders; J R Ross; K E Broadley; P M Edmonds; S Patel
Journal:  Palliat Med       Date:  2004-07       Impact factor: 4.762

Review 9.  Cancer-induced hypercalcemia.

Authors:  Franco Lumachi; Antonella Brunello; Anna Roma; Umberto Basso
Journal:  Anticancer Res       Date:  2009-05       Impact factor: 2.480

10.  Can we talk? Inpatient discussions about advance directives in a community hospital. Attending physicians' attitudes, their inpatients' wishes, and reported experience.

Authors:  B M Reilly; C R Magnussen; J Ross; J Ash; L Papa; M Wagner
Journal:  Arch Intern Med       Date:  1994-10-24
View more
  2 in total

1.  What determines the timing of discussions on forgoing anticancer treatment? A national survey of medical oncologists.

Authors:  Masanori Mori; Chikako Shimizu; Asao Ogawa; Takuji Okusaka; Saran Yoshida; Tatsuya Morita
Journal:  Support Care Cancer       Date:  2018-08-25       Impact factor: 3.603

2.  A National Survey to Systematically Identify Factors Associated With Oncologists' Attitudes Toward End-of-Life Discussions: What Determines Timing of End-of-Life Discussions?

Authors:  Masanori Mori; Chikako Shimizu; Asao Ogawa; Takuji Okusaka; Saran Yoshida; Tatsuya Morita
Journal:  Oncologist       Date:  2015-10-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.